Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015',

In this issue

Home Eurosurveillance Edition  2015: Volume 20/ Issue 27 Article 2
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 20, Issue 27, 09 July 2015
Rapid communications
Assessing the risk of observing multiple generations of Middle East respiratory syndrome (MERS) cases given an imported case
  1. Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  2. CREST, Japan Science and Technology Agency, Saitama, Japan
  3. School of Public Health, Georgia State University, Atlanta, Georgia, United States
  4. Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States
  5. The Institute of Statistical Mathematics, Tachikawa, Japan

Citation style for this article: Nishiura H, Miyamatsu Y, Chowell G, Saitoh M. Assessing the risk of observing multiple generations of Middle East respiratory syndrome (MERS) cases given an imported case. Euro Surveill. 2015;20(27):pii=21181. Article DOI:
Date of submission: 22 June 2015

To guide risk assessment, expected numbers of cases and generations were estimated, assuming a case importation of Middle East respiratory syndrome (MERS). Our analysis of 36 importation events yielded the risk of observing secondary transmission events at 22.7% (95% confidence interval: 19.3–25.1). The risks of observing generations 2, 3 and 4 were estimated at 10.5%, 6.1% and 3.9%, respectively. Countries at risk should be ready for highly variable outcomes following an importation of MERS.

Middle East respiratory syndrome (MERS) has continued to spread globally [1]. A large cluster of MERS cases has been observed in the Republic of Korea since May 2015 [2]. Until 1 July 2015, so-called quaternary cases (i.e. generation 3 counting from the index case as generation 0) have been reported in South Korea [2]. Although the inter-human transmission potential of MERS is considered to be too low to cause large-scale epidemics [3-5], high variability and heterogeneity in the transmission potential have been underscored [6]. As MERS continues to spread globally, it is vital that risk assessment involves an evaluation of the potential outcomes following MERS importation events [7]. Among a total of 23 importation events in countries outside the Middle East region, there have been four MERS case importations that have given rise to at least one secondary transmission event [2].

While the basic reproduction number R0, i.e. the average number of secondary cases produced by a primary case in a fully susceptible population, is less than 1 for MERS and a major epidemic may therefore not occur immediately, it is critical to quantitatively assess several risks of MERS transmission following an importation event, e.g. the expected numbers of cases and generations. The present study aims to analyse the observed importation events of MERS and estimate the expected size of MERS clusters and the number of generations using a stochastic epidemic model.

Importation data

Using secondary data sources [2,7-11], we extracted the numbers of secondary cases and generations for each reported importation event of MERS. We excluded data from the Kingdom of Saudi Arabia, Qatar and the United Arab Emirates from the analysis because cases in these endemic countries have frequently experienced exposures to a domestic animal reservoir (e.g. dromedary camels). Moreover, it has not been possible to fully track the transmission trees (i.e. via contact tracing data) in these countries. Including Middle East countries other than those, a total of 36 importation events were analysed. Of these, 13 events occurred in the Middle East, reported from Egypt, Iran, Jordan, Kuwait, Lebanon, Oman, Turkey and Yemen. In the present study, statistical estimation of parameters was done using two different sets of data, i.e. using all 36 importation events and restricting the analysis to the 23 importation events observed in areas outside of the Middle East. The latter data were analysed separately because the dynamics of case importation including the frequency of exposures and local contact patterns for those 23 events may not be fully comparable with the remaining 13 events.

Mathematical model

The importation event data were analysed using a branching process model which allowed us to jointly estimate the transmissibility, R0, and the dispersion parameter, k, by assuming that the distribution of secondary cases per single primary case followed a negative binomial distribution. Using the branching process model, the risk of observing at least one secondary transmission event, the risk of observing each generation of cases and the total number of cases were estimated. Hence, an important assumption to calculate these risks based on observed importation event data is that each importation event was a random sample drawn from the assumed model. For the estimation of the two model parameters, we used two different pieces of likelihood. The first one analyses the distribution of the total number of cases as described by Breban et al. for MERS [4], but the present study specifically focused on importation events [12]. Given the total number of cases z for each importation event, the likelihood to estimate R0 and k was calculated as

Equation 1:

The number of observed importation events was limited to 36 and the sample size was small. To reduce uncertainty, we analysed in addition the number of generations per importation. Considering the concept of generation to extinction, we derived the probability distribution of the number of generations, i.e.

Equation 2: 

from which we obtained the likelihood function L2 for the observed number of generations, derived from Pr(g ≤ h)-Pr(g ≤ h-1) for h > 1, i.e.

Equation 3:

and so forth. The total likelihood was given by the product of L1 and L2. The maximum likelihood method was employed to statistically infer the parameters, and the profile likelihood-based confidence intervals (CI) were computed. To account for both stochasticity and parameter uncertainty in calculating the outbreak size distribution and the risk of observing each generation of cases, the covariance matrix was used to draw random samples of R0 and k from a bivariate normal distribution with the correlation parameter informed by the matrix. The simulations were run 10,000 times, allowing us to take percentile points for the calculation of uncertainty bounds.


Figure 1 illustrates the original data employed to quantify our model.

Figure 1. Importation events of Middle East respiratory syndrome (n = 36)

The distribution of the total number of cases was right skewed, including two outbreaks with a total of at least eight cases. Excluding the Middle East countries, only the ongoing South Korean outbreak was the one that involved eight or more cases. With regard to the number of generations, three quarters of the importations (27/36) did not result in any secondary transmission. Secondary transmissions were observed in Iran, Jordan, Kuwait, France, Republic of Korea, Oman (twice), Tunisia and the United Kingdom. Excluding Middle East countries, 19 of 23 importations did not generate any secondary cases (Table 1). Among the total of 36 importations, generation 3 (or the so-called quaternary cases) was observed only for the ongoing South Korean outbreak.

Table 1. Importation of Middle East respiratory syndrome to the 23 countries outside the Middle East that have experienced case until 1 July 2015 (n = 208 cases)


Table 2 shows the estimates of R0 and k. Based on a total of 36 events, R0 and k were estimated at 0.75 (95% CI: 0.54–1.09) and 0.14 (95% CI: 0.06–0.32), respectively.

Table 2. Estimated transmission potential and dispersion parameter of Middle East respiratory syndrome based on imported case data 

The value of k was substantially smaller than 1, indicating that the distribution of secondary cases per single primary case was highly over-dispersed. Analysing the 23 importation events out of the Middle East countries, the estimates of R0 and k were 0.81 (95% CI: 0.49–1.46) and 0.07 (95% CI: 0.02–0.21), respectively. These estimates were not significantly different from those obtained using the total set of 36 importation events. For this reason, simulations were conducted using estimates derived from the full set of 36 importation events.

Figure 2 shows the expected total number of cases and the risk of observing each generation conditional on an importation event.

Figure 2. Probabilities of observing multiple generations of Middle East respiratory syndrome cases given one case importation

The risk of observing at least one secondary transmission was 22.7% (95% CI: 19.3–25.1) (Figure 2A). The risks of observing generations 2, 3 and 4 were, respectively, 10.5%, 6.1% and 3.9% (Figure 2B). When generation 2 (tertiary cases) was observed, the conditional risk of observing the next generation (quaternary cases) was as large as 63.6% (95% CI: 46.7–74.4) (Figure 2C). The outbreak size distribution appeared to be highly skewed (Figure 2D). Assuming an importation occurred, the risk of observing eight or more cases in total would be 10.9% (95% CI: 7.6–13.6).


The present study analysed importation events of MERS with a particular focus on the associated outbreak size and number of disease generations arising from each importation event. Our findings indicate that if a case of MERS was imported, at least one secondary transmission event would be observed with a probability of 22.7%. The risk of involving tertiary, quaternary and quinary cases was also calculated (Figure 2B). Although our study only relied upon importation events consisting of a small number of clusters, the estimated R0 was broadly consistent with published estimates that analysed larger cluster datasets mainly observed in Middle East countries [3-5] and was smaller than estimates derived from the early phase of hospital-associated outbreaks [13]. Considering that countries at risk of importation (i.e. countries without infected animal reservoirs) have had to confront the uncertainty associated with the risk of experiencing a case importation [14,15,16], our modelling analyses could facilitate quantitative risk assessment.

An important outcome of the present study is that the risk of observing multiple generations of MERS cases was estimated at 22.7% and that of a tertiary case at 10.5% in our model. Since the distribution of secondary cases per single primary case is highly over-dispersed, superspreading events can occur, and thus, the expected total number of cases is highly variable. The finding echoes a recent re-analysis of clusters of MERS cases reported up to August 2013 [17]. Of course, we can expect that secondary transmission events could be prevented by a combination of contact tracing, monitoring suspected cases, early diagnosis and isolation of infectious individuals. Besides, the present study suggests that countries at risk of importation should keep in mind that a large cluster of cases with multiple generations may well occur, even though R0 is clearly below the epidemic threshold at 1.0 [18].

In addition to the risk of observing a certain number of generations following an imported case, we also calculated the conditional risk of observing the next generation of case(s). This is in line with a risk assessment in real time: because the exact number of cases in a single generation cannot be manually counted during the course of an outbreak, it is reasonable to calculate the conditional risk given a generation where the conditional probability of observing the next generation is usually greater than 50%.

Two important limitations should be noted. Firstly, our exercise regarded each observed importation event as a random draw governed by the proposed probability model. Indeed, this assumption is unavoidable for fitting a branching process model to the data [3,4]. While the assumption may be common among modelling studies, it did not allow us to account for the variable type and effectiveness of interventions, especially at later generations of cases in each cluster. Secondly, MERS outbreaks have frequently been amplified in healthcare settings [6,19,20], but we limited ourselves to accounting for individual heterogeneity in a general sense. An improvement on this point was difficult, because MERS outbreaks have been seen mostly in healthcare settings without large-scale community transmission. The transmission dynamics in and out of healthcare settings have not been consistently characterised across individual outbreaks of MERS.

Despite these limitations, the present study successfully characterised the risk of observing a certain number of cases and generations given a case importation of MERS. The risk of at least one secondary case in our model was 22.7%, and that of a tertiary case was 10.5%. Once an untraced case is imported, countries at risk should assume that the secondary transmission risk as well as the risk of observing multiple generations of cases exists and should be ready to respond effectively by following their preparedness plans to manage emerging infectious diseases.

HN received funding support from the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Numbers 26670308 and 26700028, Japan Agency for Medical Research and Development, the Japan Science and Technology Agency (JST) CREST program and RISTEX program for Science of Science, Technology and Innovation Policy. GC acknowledge financial support from the Division of International Epidemiology and Population Studies, The Fogarty International Center, United States National Institutes of Health, funded in part by the Office of Pandemics and Emerging Threats at the United States Department of Health and Human Services, as well as support from grants NSF grant 1414374 as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases programme, United Kingdom Biotechnology and Biological Sciences Research Council grant BB/M008894/1 and NSF-IIS Grant#1518939. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest
None declared.

Authors’ contributions
HN conceived mathematical modelling method and analysed the data. HN, YM, GC and MS drafted and revised the manuscript.


  1. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015. Corrected proofs in press.
  2. World Health Organization (WHO). Global Alert and Response (GAR). Coronavirus infections. Geneva: WHO. [Accessed: 22 Jun 2015]. Available from:
  3. Cauchemez S, Fraser C, Van Kerkhove MD, Donnelly CA, Riley S, Rambaut A, et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect Dis. 2014;14(1):50-6. PMID:24239323
  4. Breban R, Riou J, Fontanet A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet. 2013;382(9893):694-9. PMID:23831141
  5. Chowell G, Blumberg S, Simonsen L, Miller MA, Viboud C. Synthesizing data and models for the spread of MERS-CoV, 2013: key role of index cases and hospital transmission. Epidemics. 2014;9:40-51. PMID:25480133
  6. Fisman DN, Leung GM, Lipsitch M. Nuanced risk assessment for emerging infectious diseases. Lancet. 2014;383(9913):189-90. PMID:24439726
  7. European Centre for Disease Prevention and Control (ECDC). Severe respiratory diseases associated with Middle East respiratory syndrome coronavirus (MERS-CoV). Fifteenth update – 8 March 2015. Stockholm: ECDC, 2015. Available from:
  8. Thomas HL, Zhao H, Green HK, Boddington NL, Carvalho CF, Osman HK, et al. Enhanced MERS coronavirus surveillance of travelers from the Middle East to England. Emerg Infect Dis. 2014;20(9):1562-4. PMID:25148267
  9. Yavarian J, Rezaei F, Shadab A, Soroush M, Gooya MM, Azad TM. Cluster of Middle East respiratory syndrome coronavirus infections in Iran, 2014. Emerg Infect Dis. 2015;21(2):362-4. PMID:25626079
  10. Al-Abaidani IS, Al-Maani AS, Al-Kindi HS, Al-Jardani AK, Abdel-Hady DM, Zayed BE, et al. Overview of preparedness and response for Middle East respiratory syndrome coronavirus (MERS-CoV) in Oman. Int J Infect Dis. 2014;29:309-10. PMID:25447719
  11. Hijawi B, Abdallat M, Sayaydeh A, Alqasrawi S, Haddadin A, Jaarour N, et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J. 2013;19(Suppl 1):S12-8. PMID:23888790
  12. 12. Nishiura H, Yan P, Sleeman CK, Mode CJ. Estimating the transmission potential of supercritical processes based on the final size distribution of minor outbreaks. J Theor Biol. 2012;294:48-55. PMID:22079419
  13. Majumder MS, Rivers C, Lofgren E, Fisman D. Estimation of MERS-Coronavirus Reproductive Number and Case Fatality Rate for the Spring 2014 Saudi Arabia Outbreak: Insights from Publicly Available Data. PLoS Curr. 2014;6: pii:ecurrents.outbreaks.98d2f8f3382d84f390736cd5f5fe133c. PMID: 25685622
  14. Poletto C, Gomes MF, Pastore y Piontti A, Rossi L, Bioglio L, Chao DL, et al. Assessing the impact of travel restrictions on international spread of the 2014 West African Ebola epidemic. Euro Surveill. 2014;19(42):20936. PMID:25358040</
  15. Nishiura H, Mizumoto K, Ejima K, Zhong Y, Cowling B, Omori R. Incubation period as part of the case definition of severe respiratory illness caused by a novel coronavirus. Euro Surveill. 2012;17(42):20296. PMID:23098822
  16. Ejima K, Aihara K, Nishiura H. Probabilistic differential diagnosis of Middle East respiratory syndrome (MERS) using the time from immigration to illness onset among imported cases. J Theor Biol. 2014;346:47-53. PMID:24406808
  17. Kucharski AJ, Althaus CL. The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission. Euro Surveill. 2015;20(25):21167. Available from: PMID:26132768</jrn>
  18. <jrn>18. Bauch CT, Oraby T. Assessing the pandemic potential of MERS-CoV. Lancet. 2013;382(9893):662-4. PMID:23831143
  19. Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro Surveill. 2015;20(25):21163. Available from: PMID:26132767
  20. Park HY, Lee EJ, Ryu YW, Kim Y, Kim H, Lee H, et al. Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. Euro Surveill. 2015;20(25):21169. Available from: PMID:26132766

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.